Observational study · people
Melanotan I: heavy EPP life impact fell from 75% to 0% of patients
Checked against the paper Observational studyPublished by PepVault
The takeaway
Patients with EPP on afamelanotide reported their disease weighed on their lives far less after treatment, and more of them went outside, though this comes from an uncontrolled survey.
- Kind
- Observational study
- Studied in
- People
- Published
- 2023
- Journal
- J Drugs Dermatol
What they tested
The team wanted to know how patients with erythropoietic protoporphyria (EPP), a rare disease that makes skin painfully sensitive to light, rated the benefit of afamelanotide treatment.
How the study was done
An observational questionnaire study of US patients with EPP receiving afamelanotide implants. Patients rated things like getting back to normal activities, light-triggered skin reactions and confidence on a scale running from very much to never.

What they found
Before treatment, 75% of patients said EPP affected their lives very much or a lot. After the first implant that share dropped to 11%, and after each later implant it was 0%. The number of patients who chose to go outside rose with each new implant.
What it doesn’t show
This was a self-rated patient survey with no comparison group, so it can't separate the drug's effect from other factors or from patients' expectations. It measured how patients felt about their lives, not lab or clinical measures of light sensitivity.
The paper
Resnik et al. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States. J Drugs Dermatol. 2023.
The compound
More studies on Melanotan I
- Melanotan I: more pain-free sun time in protoporphyria trialsRandomized trial · people · 2015
- Melanotan I plus UV-B: 48.64% vitiligo repigmentation at day 168Randomized trial · people · 2015
- Melanotan I: full uptake under the skin, tanning in 3 menRandomized trial · people · 1997
- Melanotan I: well tolerated in 6 acute stroke patientsClinical trial · people · 2023
- Melanotan II: erections in 17 of 20 men with erectile dysfunctionClinical trial · people · 2000
- Melanotan II: darker skin in 2 of 3 men in a small phase I trialClinical trial · people · 1996
- Every study on Melanotan I
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.